Form 4: Nuvalent Director Matthew Shair Reports Future Equity Grants and Updated Holdings

Nuvalent, Inc. Director Matthew Shair has filed a Form 4 detailing the future acquisition of restricted stock units and stock options, along with his updated beneficial ownership.

Summary

• Matthew Shair, a Director of Nuvalent, Inc. (NUVL), reported changes in his beneficial ownership through a Form 4 filing.
• On June 18, 2025, Mr. Shair is set to acquire 2,647 shares of Class A Common Stock in the form of Restricted Stock Units (RSUs) at a grant price of $0.00.
• These RSUs will vest in full on the earlier of June 18, 2026, or the date of Nuvalent, Inc.'s next annual meeting of stockholders, subject to his continued service to the company.
• Additionally, on June 18, 2025, Mr. Shair is set to acquire 4,147 stock options to buy Class A Common Stock at an exercise price of $75.53, also granted at a price of $0.00.
• These stock options will become exercisable and vest in full on the earlier of June 18, 2026, or the date of Nuvalent, Inc.'s next annual meeting of stockholders, contingent on continued service, and are set to expire on June 18, 2035.
• Following these reported transactions, Mr. Shair will beneficially own 1,429,844 shares of Class A Common Stock directly and 216,522 shares indirectly through the Matthew D. Shair 2021 Irrevocable Family Trust, over which he has voting and dispositive power.

Sentiment

Score: 7

Explanation: The filing indicates routine equity compensation for a director, which is generally a positive sign of continued alignment and commitment, without any negative implications for the company's operations or financial health.

Positives

• The grant of RSUs and stock options indicates continued alignment of a director's interests with shareholder value through equity incentives.
• The acquisition of additional equity by a director can be seen as a vote of confidence in the company's future prospects and long-term strategy.

Risks

• The vesting of both the RSUs and stock options is contingent upon Matthew Shair's continued service to Nuvalent, Inc. through the specified vesting dates, meaning the benefits are not guaranteed if his service terminates earlier.

Future Outlook

The filing indicates future equity grants to a director, with vesting scheduled for June 18, 2026, or the date of the next annual meeting, aligning management incentives with long-term company performance and strategic goals.

Industry Context

This Form 4 filing reflects a standard practice of compensating directors with equity, a common method across the biotechnology and pharmaceutical industries to align leadership incentives with shareholder interests and long-term company growth. Such grants are a routine component of executive and director compensation packages.

Comparison to Industry Standards

• The grant of RSUs and stock options at a $0.00 grant price for RSUs and an exercise price of $75.53 for options is a standard compensation practice for directors in publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• This aligns with typical equity incentive plans seen at comparable companies, where such grants are used to retain talent and incentivize performance over multi-year vesting periods, fostering long-term commitment and value creation.

Related Party Transactions

• Matthew D. Shair 2021 Irrevocable Family Trust holds 216,522 shares indirectly, over which the reporting person (Matthew Shair) has voting and dispositive power. This is a common arrangement for personal estate planning and is disclosed as an indirect beneficial ownership.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially incentivizing long-term value creation and strategic decision-making.
• Employees: The vesting conditions tied to continued service are standard for equity compensation, impacting the director's personal compensation structure and retention.

Next Steps

• Matthew Shair's continued service to Nuvalent, Inc. through the vesting dates (earlier of June 18, 2026, or the next annual meeting) for the RSUs and stock options to fully vest.
• Potential exercise of stock options by Matthew Shair on or after the vesting date and before the expiration date of June 18, 2035.

Key Dates

Recommendation

Keywords

Nuvalent Inc., NUVL, SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Director Compensation, Beneficial Ownership, Matthew Shair